Sat, Dec 20, 2014, 1:13 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Celsion Corp. Message Board

  • canstic1 canstic1 Feb 11, 2013 10:10 AM Flag

    Downside played out, good cash, ongoing trials, CLSN $2.50-$3.00 correct price

    Until we see more data...

    The company is mining the data for any subsets that looked good...Hisun has big interest to get this approved in China, 50% of all HCC in the world is in China and there is nothing of any value out there....any improve ment in the Chinese subset (200 patients) and the Chinese could approve...they do not use the same standards as the FDA...that's still 50% of the world market

    CLSN has 27 million in cash, access to another 25 million dolrars from Cantor, that 52 million dollars...no chance of bankruptcy, cash for over 2 years....

    Only 35 million shares exist, the float a much smaller 28 million, shorts 8+ million......no more downside, no more supply, real sellers are finished....

    CLSN has 2 more trials ongoing in phase 2, the RCW trial looks really really good so far.

    Not a single insider has sold a share in 5 years.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The company is mining the data for any subsets that looked good...Hisun has big interest to get this approved in China, 50% of all HCC in the world is in China and there is nothing of any value out there....any improve ment in the Chinese subset (200 patients) and the Chinese could approve...they do not use the same standards as the FDA...that's still 50% of the world market

      CLSN has 47 million in cash,...no chance of bankruptcy, cash for over 2 years....this was a preferred stock, it's NOT in the float....

      Only 35 million shares exist, the float a much smaller 28 million, shorts 8+ million......no more downside, no more supply, real sellers are finished....

      CLSN has 2 more trials ongoing in phase 2, the RCW trial looks really really good so far.

      Not a single insider has sold a share in 5 years.

    • The company is mining the data for any subsets that looked good...Hisun has big interest to get this approved in China, 50% of all HCC in the world is in China and there is nothing of any value out there....any improve ment in the Chinese subset (200 patients) and the Chinese could approve...they do not use the same standards as the FDA...that's still 50% of the world market

      CLSN has 27 million in cash, access to another 25 million dolrars from Cantor, that 52 million dollars...no chance of bankruptcy, cash for over 2 years....

      Only 35 million shares exist, the float a much smaller 28 million, shorts 8+ million......no more downside, no more supply, real sellers are finished....

      CLSN has 2 more trials ongoing in phase 2, the RCW trial looks really really good so far.

      Not a single insider has sold a share in 5 years

      .

    • read the first post in this thread. Then you'll know what is really going on at CLSN.

    • bump. read the facts

    • SeekingAlpha article today is either flat out lying or plain ignorant. Celsion has access to cash via an ATM with Cantor Fitzgerald for 25,000,000 dollars. for all we know they have already access to it in these last weeks high volume training.... we won't know until they filed the next quarterly report. together with the current 27,000,000 dollars in cash that would give Celsion 52,000,000 dollars in cash with which to operate. that is over 2 years of operating capital. why anyone would be short at a dollar 40 is beyond me. there is no downside left with that much cash on hand and the other trials still running....

    • Cans; with all due respect, I think the other side needs to be pointed out. I am not discounting what you wrote, just trying to be fair.

      Yes, they have the cash you stated. The burn rate may be accelerated as they unwind the data and correct mistakes made so that the other trials don't mirror HEAT.

      Real Sellers may be finished; but no real buyers are here either. Anyone who makes anything will cash out and play it again on the next drop. Look at the volume; this is a day trading stock now.

      How can you say the Chest Wall trial looks 'really good'? Didn't HEAT look really good too??

      No insider sells, you are right. What would be the point now?

      I'm not saying this is fairly valued at 1.50 (or whatever it is). But really, what is the value? It's unknown until that data is analyzed for something. Many (not all, but many) of the long time investors who know this technology and company inside out, have packed up and moved on. Don't you think if there was promise they would have remained at least partially invested? Now CLSN is showing up in places like Sierra Equity for Pete's sake!

      I am hanging on with a fraction of my initial investment and enjoying see the move from 1.20 to 1.45. But it is what it is, and nothing more.

      JR

      Sentiment: Hold

      • 1 Reply to reallyjollyroger
      • Fair enough JR.

        I am pressed for time and will respond later tonight. But do keep in mind the IP cost 100 million $$ to develop, is patented, and Thermodox was just one of many types of drugs that can be delivered this way, and HCC is just one disease that CLSN can target,

        Right now the company sells for just 52 million dollars, with 27 million cash in the bank, the IP and the 2 ongoing trials...

        They picked the wrong drug for the wrong disease. This is apparently how it looks to be.

        But the compamny does have cash, access to more cash and the RCW trial does actually look good, and, in my opinion, is much better suited to the drug, and the delivery method of mild hyperthermia and not ablation as was the HEAT trial...

        Now, it's not going to explode tomorrow, and I don't want people to think that's what I am saying.

        What I am saying is that this company is not even close to BK (bankrupt) as many here try to make you think, and will go on with it's trials for years to come, withoput a cash problem.

        there is still alot of value here, in my opinion, and an entry point of under $1.50 looks like a tremendous opportunity to me. Just as $9.44 was not right, neither is $1.50

        When the dust settles it will be somewhere above 2-$2.50, and if there is any positive news from the subset data, closer to $5-$6 right away...

        be back with more later,

        Cheers.

    • Entirely Agree.
      Mojo.

      Sentiment: Strong Buy

      • 1 Reply to alphamojo
      • You've got to be kidding me. Their trials are for Thermodox - which the CEO himself said that the trials "Weren't even close."

        Theres no reason to pump this POS. Its dead.

        Hisun already cancelled their deals with Celsion

        Theres no reason to think any subset data groups would have done better. If the results were closer - maybe. But the only reason people are pumping is so they can dump their shares they held through data

    • gonna run bigtime

 
CLSN
2.42+0.06(+2.54%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.